Latest: Colgate-Palmoliv Q2 FY27 (Jul–Sep 2026) results →This page is Q1 FY27 (Apr–Jun 2026).All Q1 FY27 results →
C

Colgate-Palmoliv

Q1 FY27Personal Products

Colgate-Palmoliv Q1 FY27: Capex ₹2,000 Cr

Q1 FY27 earnings call: what management said on revenue, margins and capex.

Price₹1,868
Market cap₹51.4K Cr
P/E37.5
Updated25 Aug 2026
Read3 min read

What the Q1 FY27 call signalled

1 of 3 strong

RevenueModerate growth
MarginMargins slightly down
CapexCapex planned

The short version

Colgate-Palmolive India expects continued good growth, balancing price, volume, and premium mix rather than relying solely on pricing (Page 20, 21, 29). - Premium segment is a key growth driver, growing 6 times faster than the market; significant opportunity remains as only 19% of toothpaste is currently premium priced (above 140 index) vs. Colgate-Palmolive (India) aims to sustain double-digit growth in earnings, focusing on a balanced mix of volume, premiumisation (mix), and pricing.

From Colgate-Palmoliv's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.

Revenue & Sales Performance

Moderate growth
  • Colgate-Palmolive India expects continued good growth, balancing price, volume, and premium mix rather than relying solely on pricing (Page 20, 21, 29).
  • Premium segment is a key growth driver, growing 6 times faster than the market; significant opportunity remains as only 19% of toothpaste is currently premium priced (above 140 index) vs. a potential 40-60% (Page 20, 21).
  • E-commerce and quick commerce are expanding premium product discovery and penetration, supporting higher margin growth (Page 18).
  • Growth in rural penetration (e.g., increase in daily brushing) and urban city-to-city corridor expansion also support volume growth (Pages 18, 28).

2 more points from Colgate-Palmoliv's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Colgate-Palmoliv said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Sensodyne is planning a significant capex of ₹2,000 crore, signaling a strong investment in the premium whitening toothpaste category (Page 15).
  • The company is focused on premiumisation, channel expansion including e-commerce and D2C, and investing heavily in advertising and promotions to drive growth (Pages 14, 31).
  • Colgate-Palmolive is also investing in advertising at a high level (~16% of sales), with over 50-60% advertising investment geared towards premium products to fuel growth (Page 26).
  • Sustained investment is evident in ongoing consumer outreach programs (e.g., Bright Smiles Bright Future) which are ring-fenced and growing yearly to improve oral health awareness (Page 26).

Top-ranked in Personal Products

Ranked on what management guided this quarter

Guidance-ranked
1Anondita Medi.
Rev 1Mar 1
2Recode Studios
Rev 1Mar 3
3
Rev 2Mar 2
4
Rev 3Mar 3
5
Rev 3Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Colgate-Palmoliv said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Colgate-Palmoliv said on order book & pipeline — free account, 30 seconds.

Colgate-Palmoliv — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹1.7K Cr, net profit ₹342 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Personal Products this season

  • Dabur India Ltd (Q1 FY27)

    The company remains confident about maintaining 14%-15% PAT (profit after tax) growth at consolidated level if double-digit top-line growth continues. Key…

  • Bajaj Consumer (Q1 FY27)

    Recent quarters saw exponential growth: 20% YoY in FY26 and 28% YoY in Q1 FY27, partly due to prior price corrections and strategic actions (Nishita Shanklesha…

  • Emami (Q1 FY27)

    Domestic core business grew ~6% in Q1 FY27; hair care at 11%, skin care at 3% (Rajesh Sharma, pg 13). Key concall takeaways from Emami's Q1 FY27 earnings call…

  • Godrej Consumer (Q1 FY27)

    The company reported strong broad-based revenue growth of 19% YoY and volume growth of 9%, reflecting healthy demand. Key concall takeaways from Godrej…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Colgate-Palmoliv and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Colgate-Palmoliv Q1 FY27 results?

Colgate-Palmolive India expects continued good growth, balancing price, volume, and premium mix rather than relying solely on pricing (Page 20, 21, 29). - Premium segment is a key growth driver, growing 6 times faster than the market; significant opportunity remains as only 19% of toothpaste is currently premium priced (above 140 index) vs. Colgate-Palmolive (India) aims to sustain double-digit growth in earnings, focusing on a balanced mix of volume, premiumisation (mix), and pricing.

What is Colgate-Palmoliv share price analysis?

Colgate-Palmoliv currently shows a below-average growth signal. The stock trades at a P/E of 37.5 with a market cap of ₹51,378 Cr. Investors should review the full earnings analysis for detailed insights.

Is Colgate-Palmoliv planning capital expenditure?

Sensodyne is planning a significant capex of ₹2,000 crore, signaling a strong investment in the premium whitening toothpaste category (Page 15).

Keep Colgate-Palmoliv on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.